The serotonin transporter (SERT), a primary target for many antidepressants, is expressed in the brain and also in peripheral blood cells. Although platelet SERT function is well accepted, lymphocyte SERT function has not been definitively characterized. Due to their small size, platelets often are found in peripheral blood mononuclear cell preparations aimed at isolating lymphocytes, monocytes, and macrophages. The presence of different cells makes it difficult to assign SERT expression and function to specific cell types. Here, we use flow cytometry and IDT307, a monoamine transporter substrate that fluoresces after uptake into cells, to investigate SERT function in lymphocyte and platelet populations independently, as well as simultaneously without prior isolation. We find that murine lymphocytes exhibit temperature-dependent IDT307 transport but uptake is independent of SERT. Lack of measurable SERT function in lymphocytes was corroborated by chronoamperometry using serotonin as a substrate. When we examined rhesus and human mixed blood cell populations, we found that platelets, and not lymphocytes, were primary contributors to SERT function. Overall, these findings indicate that lymphocyte SERT function is minimal. Moreover, flow cytometry, in conjunction with the fluorescent transporter substrate IDT307, can be widely applied to investigate SERT in platelets from populations of clinical significance.
U ptake by serotonin transporters (SERT) is an important mechanism for serotonin clearance from the extracellular space and one of a number of factors that regulates serotonergic neurotransmission. 1, 2 Serotonin transporters are the principal pharmacologic targets of serotonin-selective reuptake inhibiting antidepressants (SSRIs) and are believed to play a role in the etiology of neuropsychiatric disorders, including major depressive disorder (MDD), 3, 4 anxiety-related disorders, 5 and obsessive-compulsive disorder. 6 The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, the largest United States clinical trial of its kind, evaluated treatment response rates to common antidepressants in thousands of patients with MDD. 7 The results of this study indicated that only 30% of individuals diagnosed with MDD achieved remission after initial treatment with the SSRI citalopram. 8 With such low initial remission rates, it would be highly advantageous for clinicians to determine which patients with MDD are likely to respond to SSRIs prior to treatment.
Reduced [
3 H]-imipramine binding to SERT in platelets has been studied as a potential biomarker for depression, although after 30 years, consensus has not been reached as to whether depressed individuals have lower platelet SERT binding. 9, 10 By contrast, far fewer studies have focused on SERT function and of these only a handful have investigated changes in SERT function during treatment. 11−15 To date, no studies have focused on SERT function as a predictive measure of antidepressant treatment response.
Serotonin transporter regulation and function have been studied using radiometric assay, voltammetry, or fluorescence microscopy in synaptosomes, 16−18 platelets, 19, 20 peripheral blood cells (PBCs), 21, 22 lymphoblasts, 23−25 brain slices, 1 and the intact brains of experimental animals. [26] [27] [28] 2 Although SERT function can be effectively measured by all of these methods, ambiguity arises when samples containing multiple cell types, such as PBCs, are investigated due to the difficulty in assigning uptake to individual cell types. Blood cells are of particular interest because they can act as peripheral biomarkers of SERT function in neuropsychiatric diseases such as MDD. 29, 22 Additionally, characterizing SERT function in PBCs may lead to better understanding of the role of serotonin in immune cell function, 30, 31 blood pressure regulation, 32 and lymphocyte malignancies. 33, 34 The gene that is responsible for SERT expression in the brain has been shown to code for SERT in peripheral blood cells. [35] [36] [37] 20 Platelets are small 2−3 μM anucleate cell fragments derived from megakaryocytes that are primarily responsible for hemostasis and blood clotting. 38 Platelets have long been known to express SERT, 38, 32 and more recently dopamine transporter (DAT) expression has been identified in platelets. 39, 38 Serotonin transporter function has been characterized in platelets using [ 3 H]-serotonin with typical K m values reported in the nano-to micromolar range. 19, 40 Lymphocyte SERT 30, 41 and DAT 42, 43 expression have also recently been described. Serotonin transporters are reported to be expressed in primary B-lymphocytes, 41 T-lymphocytes, 41 and mixed lymphocyte populations. 44, 41, 45, 46, 21 However, others have failed to detect (or have detected only small amounts of) SERT in B-lymphocytes 33, 34 and T-lymphocytes. 30 Human lymphoblastoid cell lines, which are Epstein−Barr virusimmortalized B-lymphocytes, are also thought to express functional SERT and have been used to study human SERT gene variants. 23, 24 Other immune cells, such as monocytes 41 and dendritic cells, 30 are thought to express SERT, though these cells are rare, making them difficult to isolate in quantities necessary for studying uptake. In light of the ambiguity surrounding SERT expression, particularly in lymphocytes, it is important to determine the cell types primarily responsible for SERT function to improve future efforts aimed at predicting/ monitoring antidepressant responsiveness and to increase knowledge regarding the collective effects of SERT gene polymorphisms on SERT function.
Here, we investigated the use of IDT307, a fluorescent substrate for monoamine transporters including SERT, DAT, and norepinephrine transporters (NET), in combination with flow cytometry to delineate SERT function in mixed blood cell populations. An analogue of the nonfluorescent dopaminergic neurotoxin and DAT substrate 1-methylphenylpyridinium (MPP+), IDT307 is a twisted intramolecular charge transfer compound that fluoresces by adopting a planar conformation in hydrophobic or intercalated environments, that is, when bound to biomolecules such as protein and DNA ( Figure S1 , Supporting Information). Using flow cytometry to characterize IDT307 fluorescence, we determined SERT function in mixed cell populations where individual cell types were identified by differences in light scattering properties or surface epitopes. Across three species, our findings indicate that platelets are the major contributors to SERT function in peripheral blood cells.
■ RESULTS AND DISCUSSION
Flow Cytometry and IDT307 to Measure Serotonin Uptake. Real-time determination of SERT function was carried out using the fluorescent transporter substrate IDT307 (excitation 488 nm, emission 520 nm) in combination with flow cytometry. In HEK293 cells stably expressing SERT (SERT-HEK cells), fluorescence intensity associated with IDT307 increased with time ( Figure 1A ). Preincubation of HEK-SERT cells with paroxetine to inhibit SERT reduced time-dependent fluorescence to levels in nontransfected cells.
Concentration-dependent IDT307 uptake was investigated in SERT-HEK cells and compared to nontransfected cells. Fluorescence associated with IDT307 (1−10 μM) increased to a greater extent in SERT-HEK cells compared to HEK cells lacking SERT ( Figure 1B ). Nonspecific fluorescence in HEK cells, indicative of nonspecific binding or uptake by low affinity cation transporters, 47 was subtracted from total fluorescence associated with SERT-HEK cells at each IDT307 concentration to determine specific uptake. These data indicate that IDT307 undergoes specific transport in the presence of SERT and that uptake kinetics can be investigating using this fluorescent substrate in combination with flow cytometry.
SERT Function in Mouse Lymphocytes versus Platelets. After incubation with IDT307, mouse lymphocytes showed increases in fluorescence compared to lymphocytes that had not been incubated with IDT307. To evaluate if increased fluorescence was due to an active process, we examined the relationship between IDT307 fluorescence and temperature. Fluorescence was significantly decreased when cells were incubated at 22°C and was almost completely abolished at 4°C
, compared to 37°C (Figure 2 ), suggesting that IDT307 fluorescence in mouse lymphocytes is associated with an active uptake process.
Previously, we used chronoamperometry to quantify SERT function in mouse brain synaptosomes 16, 17 and rhesus PBCs. 21, 22 Here, we employed chronoamperometry to assess SERT function in mouse lymphocytes isolated from spleen. Unlike rhesus PBCs, the current versus time trace in Figure 3A showed no evidence of uptake of serotonin from the extracellular solution into lymphocytes, indicating minimal SERT function. To explore this apparent lack/low level of SERT function in lymphocytes further, we used flow cytometry and IDT307. Here, forward scatter of visible light gives information about cell size, while side scatter provides information about cell granularity and surface complexity. Using information inherent in the forward scatter versus side scatter plot ( Figure 3B ), a population of cells known to be lymphocytes ( Figure S2 , Supporting Information) was selectively gated in flow cytometry experiments. Incubation of mouse lymphocytes with IDT307 shifted the lymphocyte peak to the right, indicating increased fluorescence intensity ( Figure  3C ). However, coincubating lymphocytes with IDT307 and the serotonin-selective uptake inhibitor paroxetine (1 μM) failed to shift the lymphocyte peak back to lower levels of fluorescence ( Figure 3C ). Furthermore, coincubation of mouse lymphocytes with two other SERT inhibitors, S-citalopram (1 μM) or clomipramine (1 μM), similarly failed to inhibit IDT307 uptake ( Figure 3C , D). High concentrations of serotonin (500 μM) Figure 2 . Uptake of IDT307 in mouse lymphocytes is temperaturedependent. Fluorescence associated with IDT307 was significantly decreased when incubations were carried out at lower temperatures over 50 min. **P < 0.01 and ***P < 0.001 versus 37°C; † † P < 0.01 versus 22°C; N = 3 per temperature. were also unable to compete with IDT307 uptake. Together, these data show that IDT307, but not serotonin, is actively transported by mouse lymphocytes; however, IDT307 uptake is not occurring via SERT.
Compared to lymphocytes, platelets are known to have high levels of SERT protein 19, 20, 45 and to take up 19, 20 and to release serotonin. 48, 49 We investigated uptake of IDT307 by flow cytometry in platelet-rich plasma isolated from mice and observed that lower concentrations of paroxetine (100 nM) or S-citalopram (100 nM) inhibited IDT307 uptake into mouse platelets (Figure 4 ).
Rhesus and Human Platelets but Not Lymphocytes Exhibit Measurable SERT Function. To determine if the lack of SERT function in mouse lymphocytes was speciesspecific, we examined IDT307 uptake in PBCs isolated from human or rhesus whole blood. Additionally, we used chronoamperometry to measure SERT function in human platelet-rich plasma versus human PBCs that were extensively washed to remove platelets. Figure 5 shows a comparison of the results obtained by both methods. Using chronoamperometry, clearance of serotonin by human platelets was readily observed at a rate of 0.46 ± 0.1 pmol/10 6 platelet × min ( Figure 5A ), whereas in isolated lymphocytes uptake was minimal to nonexistent; that is, the change in serotonin current over 20 min was <10% ( Figure 5B) .
Coincubation of human PBCs with IDT307 and paroxetine, citalopram, clomipramine, or serotonin failed to show evidence of SERT-specific uptake when lymphocytes were selectively analyzed ( Figures 5D and 6A) . Interestingly, high concentrations of imipramine (100 μM), which have been used to inhibit serotonin uptake in lymphoblasts, 23 reduced IDT307 uptake in human lymphocytes by approximately 40% ( Figure  6A ). However, at this concentration, imipramine is likely to interact nonselectively with unknown transporters, in addition to SERT (K i (SERT) = 140 ± 40 nM 50 ). Similarly, coincubations of rhesus PBCs with IDT307 and two different concentrations of S-citalopram (100 nm, 1 μM) or serotonin (500 μM) were used to investigate SERT-specific uptake by flow cytometry. Consistent with mouse and human lymphocyte experiments, selective gating for rhesus lymphocytes showed IDT307-associated fluorescence, but this was independent of SERT ( Figure 6C) .
Peripheral blood cells isolated from whole blood, as opposed to lymphocytes from spleen, contain large numbers of platelets, in addition to mononuclear cells such as lymphocytes. In flow cytometry, the platelet population can be distinguished from the lymphocyte population on the basis of light scattering characteristics ( Figure 5C ) and dead cells of all types can be identified via propidium iodide staining ( Figure S3 , Supporting Information). Furthermore, platelets can be differentiated from lymphocytes through the use of cell-specific surface markers ( Figure S4 , Supporting Information). Concurrent with lymphocyte uptake, we examined IDT307 transport by human and rhesus platelets in PBC preparations. Paroxetine, S-citalopram, and clomipramine reduced human and rhesus platelet IDT307 uptake to <5% and <20% of total uptake, respectively, confirming that the majority of IDT307 uptake in platelets is mediated by SERT ( Figures 5E and 6B, D) . Furthermore, in contrast to lymphocytes, serotonin competed effectively for IDT307 uptake in platelets.
The primary finding of the present study is that platelets, not lymphocytes, contribute to the majority of SERT function in Ficoll-separated peripheral blood cells. Others and we have previously reported that lymphocytes and lymphoblastoid cell lines express functional SERT. 23, 24, 41, 21, 51 However, the chronoamperometry and flow cytometry results presented here are not in strong agreement with prior findings. It is possible that lymphocytes express SERT but that, in nonactivated or nonmalignant cells, surface SERT localization is absent or present only in very low amounts. Others have failed to detect the presence of surface SERT on lymphocytes. 30 The promiscuity of IDT307 for other transporters might also interfere with the ability to detect small changes in IDT307 fluorescence associated with low levels of SERT function, although the chronoamperometry findings using the native substrate for SERT (serotonin) do not support this idea. Fluorescence-activated cell sorting (FACS) to isolate lymphocyte and platelet fractions will be used in the future to compare relative surface SERT protein levels across different cell populations.
An additional finding is the probability of an unidentified transporter on lymphocytes that takes-up IDT307. In platelets, we hypothesize that SERT contributes to the majority of IDT307 uptake because almost complete inhibition of uptake was observed in the presence of SERT inhibitors (Table 1) . However, in lymphocytes, uptake of IDT307 was not inhibited by coincubation with SERT inhibitors. Furthermore, although other laboratories have found evidence of DAT 42, 43 and NET 52 expression in lymphocytes, DAT and NET inhibitors failed to reduce IDT307 fluorescence (data not shown). Low affinity/ high capacity organic cation transporters (OCT) can transport positively charged substrates like IDT307. 47 Moreover, OCT-3 has been shown to transport serotonin at high concentrations under conditions of low SERT capacity. 27, 53 Since OCT-3 expression has not been explored in lymphocytes, we carried out preliminary experiments with IDT307 and coincubation with the OCT-3 inhibitor decynium-22. However, decynium-22 fluoresces at the emission wavelength used to detect IDT307 (520 nm), complicating evaluation of its inhibitory potency by flow cytometry. Nonetheless, a high concentration of serotonin failed to inhibit IDT307 uptake into lymphocytes, arguing against a role for OCT-3 or other decynium-22 sensitive transporters, including OCT1, OCT2, and the plasma membrane monoamine transporter (PMAT).
The use of flow cytometry has multiple advantages over other techniques to study monoamine transporter function. Flow cytometry enables transporter function to be differentiated in mixed cell populations on the basis of cell type. Using light scattering properties or fluorescent antibody labeling of cell-surface markers, different cell populations can be identified and analyzed with respect to IDT307-associated fluorescence. Radiometric uptake, voltammetry, or analysis of fluorescent substrates using microplate readers require that distinct cell populations be separated since these methods can not differentiate uptake by cell type. Furthermore, fluorescence associated with individual cells is measured by flow cytometry enabling variance within cell populations to be evaluated. Further, flow cytometry is optimized for cells such as lymphocytes that grow suspended in media, unlike HEK293 cells, which are adherent cell lines used in transfection and overexpression studies.
Although radiometric methods are a cornerstone for studying transporter function, the goals and limitations of particular types of experiments must be considered. Moreover, fluorescence-based techniques have already replaced radiometric methods to advantage in many important areas, for example, DNA sequencing and gene expression analysis. There are multiple benefits associated with using a fluorescent substrate for monoamine transporters. For example, receptor modulation of transporter function can be differentiated based on the selectivity of nonnative substrates versus endogenous substrates for transporters over receptors. Others have shown using ASP+, another fluorescent MPP+ analogue ( Figure S1 , Supporting Information), that DAT is regulated by activation of D2 and D3 dopamine receptors. 54 Unlike dopamine, ASP+ interacts selectively with DAT versus dopamine receptors. Similarly, flow cytometry, in combination with IDT307, could be used to examine SERT/5-HT1A receptor interactions in immune cells. 55 There are some drawbacks to using IDT307, which is a promiscuous substrate for multiple transporters. While IDT307 can be used to study the function of multiple transporters in native cells experiments must be carefully designed. This is evidenced by the findings of temperaturedependent yet SERT-independent IDT307 uptake in lymphocytes.
The use of peripheral blood cells as biomarkers for central nervous system function has the potential to impact the diagnosis and treatment of neuropsychiatric disorders. Others have begun to examine immune cells as biomarkers for neurological diseases such as Parkinson's disease, 56 multiple system atrophy, 43 and amyotrophic lateral sclerosis. 42 We are currently investigating SERT function using chronoamperometry in PBCs from patients with MDD to predict treatment effectiveness. By looking directly at SERT function, we hope to circumvent the need to identify and to understand the contributions of a large number of known and unknown genetic factors that may influence antidepressant responses. Unlike chronoamperometry, flow cytometry is commonly found in most major clinical and research centers enabling biomarker assays to be put into clinical practice faster and with more ease. 29 Moreover, a miniaturized fluorescent microscope and flow cytometer coupled to a cell phone have been recently demonstrated and could form the basis of future personalized medicine/remote analysis approaches. 57, 58 Understanding the relationship between pretreatment SERT function 29, 22 or changes in uptake occurring early in treatment 59 and therapeutic outcomes might give clinicians the ability to prescribe certain classes of drugs for different patients with greater reliably. With high treatment uncertainty in current approaches, these types of advances are necessary for the realization of personalized medicine.
■ EXPERIMENTAL PROCEDURES
Chemicals and Drugs. IDT307 was synthesized and characterized by standard methods at Vanderbilt University. Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), and propidium iodide (PI) were purchased from Life Technologies (Grand Island, NY). Serotonin (5-HT), paroxetine (PRX), imipramine (IMI), NH 4 Cl, KHCO 3 , Na 2 EDTA, DMSO, and prostaglandin E1 were purchased from Sigma-Aldrich (St Louis, MO). Clomipramine (CMI) was purchased from Sigma Aldrich/RBI (Natick, MA). S-Citalopram (S-CIT) was from Biotrend (Destin, FL). Penicillin/streptomycin was purchased from Fisher Scientific (Pittsburgh, PA). Chemicals used for the assay buffer were purchased from VWR (West Chester, PA).
HEK293 Cells. Human embryonic kidney-293 cells (HEK293) and SERT-transfected HEK293 cells were cultured until confluent at 37°C in 5% CO 2 in DMEM containing 10% FBS and 1% penicillin/ streptomycin. Prior to uptake experiments, cells were gently dissociated from the bottoms of culture flasks using trituration with a serological pipet. Cell suspensions were centrifuged at 100g and resuspended in assay buffer (150 mM NaCl, 5 mM KCl, 1.2 mM MgCl 2 , 5 mM glucose, 10 mM HEPES, 2 mM CaCl 2 ; pH 7.4). 21 For real-time experiments, IDT307 (3 μM) was added 60 s after beginning fluorescence measurements. Uptake was monitored for an additional 10 min with fluorescence averaged every 20 s. For saturation experiments, HEK293 cells and HEK-SERT cells were incubated with different concentrations of IDT307 (1.0−10.0 μM) at room temperature for 10 min. Cells were then centrifuged at 100g and resuspended in fresh assay buffer.
Mouse Lymphocytes and Platelets. All procedures involving animals were carried out in accordance with National Institutes of Health Animal Care and Use Guidelines and were approved by the Pennsylvania State University Animal Care and Use Committee or the University of California, Los Angeles Chancellor's Animal Research Committee. For lymphocyte isolations, mice were anesthetized with 5% isoflurane, euthanized immediately by cervical dislocation, and the spleens were rapidly removed and homogenized in 15 mL of sterile 2% FBS in phosphate buffered saline (2% FBS/PBS). Homogenates were centrifuged at 500g and resuspended in 5 mL of ACK lysis buffer (0.15 M NH 4 Cl, 0.01 M KHCO 3 , 0.1 mM Na 2 EDTA, pH 7.2−7.4) to remove the majority of red blood cells. Lysis was stopped by the addition of 40 mL of cold 2% FBS/PBS. The lysis solution was removed by centrifugation at 500g for 10 min. Cells were resuspended in 10 mL of cold 2% FBS/PBS and filtered through 40 μm nylon mesh filters to obtain lymphocytes.
To isolate mouse platelets, trunk blood was collected into heparinized capillaries (Drummond Scientific Company, Broomall, PA). Blood was pooled in 1.5 mL Eppendorf tubes and 1/2 volume 150 mM NaCl/10 mM HEPES/1 mM EDTA; pH 7.4 was added. Samples were centrifuged at 300g for 15 min to isolate platelet rich plasma (PRP), which was removed and placed into fresh 1.5 mL Eppendorf tubes. Prostaglandin E1 was added to PRP for a final concentration of 1 μM to inhibit platelet activation. Samples were centrifuged at 1000g for 10 min and platelet pellets were resuspended in assay buffer prior to uptake measurements.
Rhesus and Human Peripheral Blood Cells. Whole blood was collected in 10 mL tubes containing 158 USP units of sodium heparin (BD Vacutainer, Franklin Lakes, NJ). Blood was transferred into 50 mL conical tubes, and PBS was added for a total volume of 30 mL. Blood/PBS solutions were layered on 15 mL of Ficoll-Plaque solution (GE Healthcare, Uppsala, Sweden) and centrifuged at 1400g for 20 min with no brake. The buffy layer (containing peripheral blood mononuclear cells and platelets) was removed and washed twice with PBS followed each time by a 15 min spin at 500g. Cells were resuspended in 90% FBS/10% DMSO and placed into a Mr. Frosty freezing chamber overnight at −80°C. Just prior to experiments, cells were gently thawed for 2 min and then quickly poured into 12 mL of fresh assay buffer. Cells were centrifuged at 500g for 6 min. Supernatants were removed, and cells were resuspended in assay buffer.
To isolate human platelet-rich plasma and lymphocytes, whole blood samples (20 mL) were centrifuged at 200g for 15 min to pellet red blood cells and mononuclear cells. The PRP supernatants were removed and placed into fresh centrifuge tubes. Prostaglandin E1 was added to a final concentration of 1 μM to prevent platelet activation. Samples of PRP were centrifuged at 2500g for 5 min, washed once with 2 mL PBS, and then centrifuged again at 2500g for 5 min. Platelets were resuspended in assay buffer and used for chronoamperometry. For chronoamperometry experiments using isolated lymphocytes, PBCs from Ficoll separations were washed with PBS (10 mL) three additional times and centrifuged after each wash at 100g for 10 min to remove platelets. Cell samples were examined using light microscopy to verify that most platelets had been removed.
IDT307 Uptake and Flow Cytometry. Following isolation, mouse, rhesus, or human peripheral blood cells were centrifuged for 10 min at 500g. Supernatants were removed, and cells were resuspended in fresh 37°C assay buffer. Experiments for each treatment per animal were conducted in duplicate. Cells for all experiments were counted manually using a hemocytometer. Cells were divided equally (10 6 cells/mL) into 1.5 mL Eppendorf tubes and individual drugs or serotonin were added to specific tubes. Samples were placed in a 37°C incubator for 10−20 min to allow time for drug diffusion/binding. After preincubation, 1.5 μM IDT307 was added and samples were further incubated for 50 min at 37°C. The concentration of IDT307 used in PBC experiments was associated with maximal uptake above which nonspecific fluorescence increased substantially. Following incubation, cells were centrifuged for 10 min at 500g and resuspended in fresh, cold assay buffer to terminate uptake. For temperature dependence experiments, cells were incubated at different temperatures prior to and during uptake of 1.5 μM IDT307. Propidium iodide was added to each sample prior to cytometric analysis to assay dead cells ( Figure S3, Supporting Information) . A Becton Dickinson FACScalibur flow cytometer or a Coulter FC500 flow cytometer was used to carry out flow cytometry. Propidium iodide and IDT307 were excited with a 488 nm laser, and fluorescence was monitored at 520 nm for IDT307 and 585 nm for PI.
Chronoamperometry. Experiments using chronoamperometry and boron-doped diamond electrodes were carried out as previously described. 21 Samples containing mouse splenocytes (∼35 million cells), human lymphocytes (∼10 million cells), or human platelets (∼350 million cells) were placed into single wells of a 12-well plate in 2 mL assay buffer. Working and reference electrodes were stabilized in cells suspensions, after which serotonin was injected into each well at a final concentration of 750 nM. Uptake was measured over 20 min followed by postcalibration.
Data Analysis. Flow cytometry data were analyzed using FCS Express (De Novo Software, Los Angeles, CA). Propidium iodide fluorescence was analyzed to distinguish IDT307 fluorescence associated with live cells. Individual cell types have unique light scattering properties based on differences in cell size (forward scatter) and granularity (side scatter). Gating on these properties, in combination with identification via fluorescently labeled cell surface epitopes or dead cells, enables changes in IDT307 fluorescence to be analyzed in specific populations of cells. 60 After selectively gating on lymphocytes or platelets, median fluorescence intensities in the detector at the IDT307 emission wavelength were used to determine background fluorescence of cells in the absence of IDT307. Sets of samples that were incubated with drugs or serotonin included samples where IDT307 was excluded to assess background fluorescence associated with the drugs themselves. GraphPad Prism (GraphPad Software, La Jolla, CA) was used for graphing and statistical analysis. 
